论文部分内容阅读
目前研究已证实勃起功能障碍(ED)和良性前列腺增生(BPH)之间除了有高龄等共同危险因素外,在流行病学上也具有相关关系。虽然目前的研究尚不能得出直接的因果关系,但包括一氧化氮生物利用度改变,自主神经系统和α1受体功能亢进,RhoA/Rhod激酶通路异常及代谢综合征等多种因素在ED和BPH的发病中均起到重要作用。因此对BPH患者进行评估治疗时,应同时筛查性功能指标,判断是否同时合并有ED。多项临床研究发现他达拉非等PDE5抑制剂在ED合并BPH相关下尿路症状的治疗中效果良好,这为进一步研究ED合并BPH的治疗和预防奠定了基础。
The current study has confirmed that there is a correlation between epidemiology and erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) in addition to common risk factors such as age. Although no direct causal relationship can be drawn from the present study, there are many factors including changes in bioavailability of nitric oxide, autonomic nervous system and α1 receptor hyperactivity, abnormality of RhoA / Rhod kinase pathway and metabolic syndrome, BPH play an important role in the pathogenesis. Therefore, the evaluation of BPH patients treated should be screened at the same time sexual function indicators to determine whether at the same time with ED. Several clinical studies have found that PDE5 inhibitor such as tadalafil works well in the treatment of urinary tract symptoms associated with ED with BPH, which lays the foundation for further study on the treatment and prevention of ED combined with BPH.